CABA Cabaletta Bio Inc: Long-Term Debt to Capital Coefficient

Symbol and logo of brand Cabaletta Bio Inc (CABA)

The confirmed price history on the Cabaletta Bio, Inc. (CABA) chart unfolds within a stable US legal framework, where developments are protected by international humanitarian law. Cabaletta Bio, Inc. (CABA) revenues are based on the implementation of CART-cell therapy against severe autoimmune pathologies. The business also relies on exclusive patents in the field of skin disease treatment, which ensures the uniqueness of its offerings. The current indicator is 0.03.

CABA - Cabaletta Bio Inc. Long-Term Debt to Equity over the range 07/04/2022 - 10/28/2026

Comprehensive metric breakdowns and analytics for Cabaletta Bio, Inc. (CABA)

- price and consensus price forecast:
Quote Chart Cabaletta Bio Inc.|CABA - Analyst Consensus Forecast
- market capitalization data:
Market Value Cabaletta Bio|CABA - Enterprise Value
- book capitalization data:
Book Value per Share Cabaletta Bio, Inc.|CABA - Company Book Value|Market Value to Book Value cabalettabio.com|CABA - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Cabaletta Bio, Inc.|CABA - Long-Term Debt to Capital|Short-Term Debt to Capital cabalettabio.com|CABA - Company Total Debt|Debt to Net Assets Ratio Cabaletta Bio
Initial company analysis:CABA, Cabaletta Bio Inc.
Core merchandise of Cabaletta Bio, Inc.

Conservative capital demands transparency regarding debt loads to assess business resilience to systemic shocks. This indicator correlates liabilities with maturities exceeding one year against equity, determining the degree of financial leverage and dependence on borrowed funds. Amid FDA regulatory risks and threats of CAR-T therapy side effects, the long-term debt-to-equity chart confirms the margin of safety for Cabaletta Bio, Inc. (CABA).

Direct competitors

Long-Term Liabilities to Equity argenx N.V.|BioNTech Group (BNTX) - Long-Term Debt to Capital|Long-Term Debt to Capital Coefficient Abivax S.A. (ABVX)|Long-Term Debt to Capital ADMA (ADMA Biologics)|protagonist-inc.com - Long-Term Debt to Capital|Long-Term Debt to Equity Immunovant (IMVT)|KNSA: Long-Term Debt to Capital Coefficient|GRFS (Grifols Group) - Long-Term Debt to Equity|Adaptive Biotechnologies Inc. (ADPT) - Long-Term Debt to Equity Ratio|CLDX (Celldex Therapeutics) - Long-Term Debt to Capital|Long-Term Debt to Capital auriniapharma.com (AUPH)|BioCryst Pharmaceuticals (BCRX) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient Vera Therapeutics Inc (VERA)|Long-Term Debt to Capital DNTH|Pharvaris Pharma - Ratio of Long-Term Indebtedness to Capital|ABCL: Long-Term Debt to Equity|TRML: Long-Term Debt to Equity Ratio|PGEN (Precigen) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Pharming Group NV|NKTR (Nektar) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital UPB|Long-Term Debt to Equity Zenas Biopharma Inc ZBIO|Long-Term Debt to Capital Ratio immunome.com (IMNM)|GOSS: Long-Term Debt to Capital|Long-Term Liabilities to Capital KalVista Pharma KALV|SEPN: Long-Term Debt to Capital|PVLA - Long-Term Debt to Equity Ratio|SVRA: Long-Term Debt to Capital|rigel.com (RIGL) - Long-Term Debt to Capital|Long-Term Debt to Capital AnaptysBio|Long-Term Debt to Equity Astria Therapeutics Inc|Long-Term Debt to Capital ENGN|Long-Term Debt to Capital RAPT (rapt.com)|Long-Term Debt to Equity Aerovate Therapeutics JBIO|Long-Term Debt to Equity aclaristx.com ACRS|KYTX (Kyverna Therapeutics, Inc.) - Long-Term Debt to Capital|Tiziana Life Sciences Ltd. (TLSA) - Long-Term Liabilities to Capital|VTYX - Long-Term Debt to Equity Ratio|Long-Term Loans to Capital Ratio Theratechnologies, Inc|Avalo Therapeutics, Inc (AVTX) - Long-Term Debt to Equity Ratio|Long-Term Loans to Capital Ratio eledon.com|Long-Term Debt to Capital AGEN|Long-Term Debt to Capital Climb Bio Inc. CLYM|Long-Term Debt to Equity Ratio Zura Bio Limited|Long-Term Debt to Capital Coefficient aTyr Pharmaceuticals ATYR|ADAG - Long-Term Debt to Capital|IMA - Long-Term Debt to Equity|shattucklabs.com - Long-Term Debt to Capital|EQ (Equillium) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity CNTB (Connect Biopharma Holdings)|Long-Term Liabilities to Capital Immunic Inc (IMUX)|Atara Biotherapeutics (ATRA) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient inflarx.de (IFRX)|Long-Term Debt to Capital XFOR|Adicet Bio Inc. - Ratio of Long-Term Indebtedness to Capital|Celularity Corp (CELU) - Long-Term Debt to Equity|INMB - Long-Term Debt to Capital Ratio|BRNS (Barinthus Biotherapeutics) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio kezarlifesciences.com|SABS: Long-Term Debt to Equity Ratio|Ratio of Long-Term Indebtedness to Capital Akari Therapeutics PLC|Long-Term Debt to Capital ENLV (Enlivex Therapeutics)|Long-Term Debt to Equity Ratio q32bio.com (QTTB)|Long-Term Debt to Capital GOVX (GeoVax Labs, Inc.)|Long-Term Debt to Capital edesabiotech.com EDSA|IBIO - Long-Term Debt to Capital|CARM - Long-Term Debt to Equity|XTLB: Long-Term Debt to Capital|BOLT (Bolt Biotherapeutics, Inc.) - Long-Term Debt to Capital|Long-Term Debt to Equity HCW Biologics, Inc. HCWB|Long-Term Liabilities to Equity Aptevo|AIM ImmunoTech (AIM) - Long-Term Debt to Capital|Long-Term Debt to Capital Coefficient aditxt.com (ADTX)|Long-Term Debt to Capital GRI (GRI Bio Corp)|XORTX Corp - Long-Term Debt to Capital|Long-Term Debt to Equity Vyome Holdings Inc (HIND)|REVB: Long-Term Debt to Capital Coefficient|INDP (Indaptus Therapeutics, Inc.) - Long-Term Debt to Equity|Scinai Immunotherapeutics Ltd (SCNI) - Long-Term Debt to Equity Ratio|CALI (CalciMedica Inc) - Long-Term Debt to Capital|Long-Term Debt to Capital Affimed Therapeutics (AFMD)|Allakos Inc. (ALLK) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient hookipapharma.com (HOOK)|Long-Term Debt to Capital IGMS|iTeos Therapeutics Inc - Ratio of Long-Term Indebtedness to Capital|OCEA: Long-Term Debt to Equity|TCBP: Long-Term Debt to Equity Ratio|THRD (Third Harmonic Bio) - Long-Term Debt to Equity